15,240 Gilead Sciences, Inc. $GILD Shares Bought by CWA Asset Management Group LLC

Key Points

• CWA Asset Management Group increased its Gilead Sciences stake by 24% in the third quarter, buying 15,240 shares and bringing its holdings to 78,639 shares valued at approximately $11.7 million. Institutional investors and hedge funds collectively own 83.67% of Gilead.
• Gilead reported quarterly revenue of $7.8 billion, exceeding the $7.4 billion consensus estimate, while adjusted EPS also beat expectations. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $159.33.
• The company declared a quarterly dividend of $0.82 per share, equivalent to $3.28 annually and a 2.1% yield. Gilead shares opened at $153.07, after trading between $114.02 and $160.51 over the prior year.

CWA Asset Management Group LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 24.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,639 shares of the biopharmaceutical company's stock after acquiring an additional 15,240 shares during the period. CWA Asset Management Group LLC's holdings in Gilead Sciences were worth $11,721,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Warwick Investment Management Inc. bought a new stake in shares of Gilead Sciences in the third quarter valued at about $213,000. Retirement Planning Group LLC grew its holdings in shares of Gilead Sciences by 26.6% during the third quarter. Retirement Planning Group LLC now owns 2,713 shares of the biopharmaceutical company's stock worth $404,000 after buying an additional 570 shares in the last quarter. Tanager Wealth Management LLP bought a new position in shares of Gilead Sciences during the third quarter worth about $217,000. Trellis Wealth Advisors LLC bought a new position in shares of Gilead Sciences during the third quarter worth about $33,000. Finally, Clark Financial Services Group Inc. BD raised its position in Gilead Sciences by 14.0% in the 3rd quarter. Clark Financial Services Group Inc. BD now owns 4,732 shares of the biopharmaceutical company's stock valued at $705,000 after buying an additional 581 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 2.0%

Shares of GILD stock opened at $153.07 on Tuesday. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company has a fifty day moving average price of $147.59 and a two-hundred day moving average price of $137.39. Gilead Sciences, Inc. has a one year low of $114.02 and a one year high of $160.51.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company's quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.01 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post -0.47 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were issued a dividend of $0.82 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. Gilead Sciences's dividend payout ratio (DPR) is presently -122.85%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on GILD shares. Weiss Ratings upgraded Gilead Sciences from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, September 14th. Royal Bank Of Canada upped their price target on Gilead Sciences from $123.00 to $126.00 and gave the stock a "sector perform" rating in a research report on Thursday, October 8th. Morgan Stanley decreased their price target on shares of Gilead Sciences from $165.00 to $163.00 and set an "overweight" rating for the company in a research note on Wednesday, October 7th. Truist Financial lifted their price objective on shares of Gilead Sciences from $150.00 to $158.00 and gave the company a "buy" rating in a report on Wednesday, October 7th. Finally, Zacks Research lowered shares of Gilead Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 29th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $159.33.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Anthony Welters sold 18,000 shares of the company's stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director owned 12,894 shares in the company, valued at $1,916,306.28. This represents a 58.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $137.64, for a total value of $3,853,920.00. Following the completion of the sale, the insider directly owned 118,234 shares of the company's stock, valued at approximately $16,273,727.76. The trade was a 19.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 111,000 shares of company stock valued at $15,877,860 in the last three months. Corporate insiders own 0.30% of the company's stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported positive Phase 2 SWIFT trial results for emvistegrast, an oral treatment for active ulcerative colitis. The drug met the trial’s primary goal, strengthening Gilead’s inflammatory bowel disease pipeline and providing potential long-term diversification beyond its HIV franchise. Gilead's pill succeeds in mid-stage bowel disease trial
• Positive Sentiment: Analysts at Zacks upgraded GILD to Rank #2, or “Buy,” citing improving earnings prospects. The upgrade could support near-term investor interest, although it is a ratings-based catalyst rather than a change to the company’s fundamentals. All You Need to Know About Gilead Rating Upgrade to Buy
• Positive Sentiment: Gilead said it will present 28 studies at IDWeek 2026 covering HIV treatment, prevention and emerging antiviral programs. The presentations could provide additional visibility into future products and support expectations for continued innovation. Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
• Neutral Sentiment: Reports highlighted Gilead’s recent FDA approvals and label expansions, while ETF activity showed that 43 funds added the stock. These developments may improve sentiment, but they do not necessarily create immediate revenue or earnings changes.
• Negative Sentiment: Investors remain focused on whether acquisitions of Arcellx and Tubulis will enhance profits or dilute the dependable returns generated by Gilead’s HIV portfolio and dividend. This integration and capital-allocation uncertainty may have limited the market’s reaction to the ulcerative-colitis trial success. What Has Changed About Owning Gilead Stock?
• Negative Sentiment: Two insiders, Andrew Dickinson and Johanna Mercier, each reportedly sold 3,000 shares. The transactions are modest relative to Gilead’s market capitalization but can add a slightly cautious signal.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.